Company’s 36-month beta value is 0.98.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MREO is 141.76M, and currently, short sellers hold a 3.22% ratio of that floaft. The average trading volume of MREO on November 15, 2024 was 753.51K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MREO) stock’s latest price update
Mereo Biopharma Group Plc ADR (NASDAQ: MREO)’s stock price has plunge by -5.68relation to previous closing price of 4.05. Nevertheless, the company has seen a -6.60% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-14 that LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT.
MREO’s Market Performance
Mereo Biopharma Group Plc ADR (MREO) has experienced a -6.60% fall in stock performance for the past week, with a -15.30% drop in the past month, and a -11.78% drop in the past quarter. The volatility ratio for the week is 6.35%, and the volatility levels for the past 30 days are at 4.87% for MREO. The simple moving average for the past 20 days is -9.41% for MREO’s stock, with a 1.64% simple moving average for the past 200 days.
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with Robert W. Baird repeating the rating for MREO by listing it as a “Outperform.” The predicted price for MREO in the upcoming period, according to Robert W. Baird is $8 based on the research report published on June 13, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see MREO reach a price target of $4. The rating they have provided for MREO stocks is “Buy” according to the report published on October 13th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to MREO, setting the target price at $4 in the report published on August 12th of the previous year.
MREO Trading at -10.42% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.90% of loss for the given period.
Volatility was left at 4.87%, however, over the last 30 days, the volatility rate increased by 6.35%, as shares sank -16.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.77% lower at present.
During the last 5 trading sessions, MREO fell by -6.60%, in comparison to the 20-day moving average, which settled at $4.22. In addition, Mereo Biopharma Group Plc ADR saw 65.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MREO starting from Scots-Knight Denise, who sale 60,046 shares at the price of $4.22 back on Sep 13 ’24. After this action, Scots-Knight Denise now owns 808,921 shares of Mereo Biopharma Group Plc ADR, valued at $253,454 using the latest closing price.
Scots-Knight Denise, the Chief Executive Officer of Mereo Biopharma Group Plc ADR, sale 28,611 shares at $4.47 during a trade that took place back on Sep 12 ’24, which means that Scots-Knight Denise is holding 868,967 shares at $127,968 based on the most recent closing price.
Stock Fundamentals for MREO
Current profitability levels for the company are sitting at:
- -38.66 for the present operating margin
- -0.03 for the gross margin
The net margin for Mereo Biopharma Group Plc ADR stands at -37.81. The total capital return value is set at -0.43.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.74. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 9.61.
Currently, EBITDA for the company is -26.06 million with net debt to EBITDA at 2.31. When we switch over and look at the enterprise to sales, we see a ratio of 565.78. The receivables turnover for the company is 0.33for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.10.
Conclusion
In a nutshell, Mereo Biopharma Group Plc ADR (MREO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
